In this conversation between Rebecca Johnson, PhD, ACT EAB member and clinical research recruitment and inclusion executive ...
In today's ACT Brief, we examine leadership instability and regulatory uncertainty during Makary's FDA tenure, how lived ...
Week-24 TRuE-AD4 outcomes with ruxolitinib 1.5% cream showed 84.3% EASI75 and 70.6% IGA Treatment Success among completers ...
In today's ACT Brief, we examine cost models for imaging infrastructure in clinical trials, how community relationships ...
FDA Commissioner Marty Makary, MD, MPH, resigned Tuesday, according to The Associated Press, just 13 months after being ...
On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...
In this Q&A, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, discusses how clinical ...
A multi-stakeholder tabletop exercise evaluated SSDC integration into pragmatic trials, emphasizing fit-for-purpose safety ...
Lastly, a broader view of clinical outcomes and operational insights is a cornerstone to product value translation. Gathering ...
A phase 3 trial evaluating Moderna’s investigational seasonal influenza vaccine, mRNA-1010, found the messenger RNA ...
Execution instability often originates in strategy timing rather than study conduct, which sponsors can correct by ...
LUCENT-3 trial open-label extension data show 63.5% of adults with ulcerative colitis administered mirikizumab (Omvoh) who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results